AARD_OUT_1 [2025-04-28 13:21:00 -0400] 3670 Bytes | 972 tokens | Cum: 972 tkns (12.15% of 8k)
==========================================================================

Listen up, partner—it's 1:20 PM on Mon Apr 28, 2025, and I’m revved up about Aardvark Therapeutics (AARD), climbing from $7.93 to $9.23. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Aardvark Therapeutics (AARD)
IPO: 2025-02-13 (2 Months Ago)
Market Cap: $177,276,485
Shares Outstanding: 21,380,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Here’s a list of headlines for Aardvark Therapeutics:

Mar-31-25 04:10PM - Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
Mar-27-25 04:18PM - Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
Mar-21-25 09:20AM - Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory
Mar-14-25 11:25AM - Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month
Mar-03-25 02:55PM - Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently
Feb-12-25 10:38PM - Aardvark Therapeutics Announces Pricing of Initial Public Offering

Prior AI Reports for AARD:
1. 2025-04-04 – Score: 35 – Target: 7.5000 – Highs: 8.8400 / 8.2704 / 8.30
aardvark-therapeutics-inc-faces-market-headwinds-amid-insider-trading
2. 2025-04-01 – Score: 50 – Target: 9.0400 – Highs: 9.7000 / 9.4200 / 9.19
mixed-signals-declining-performance-amid-insider-trading-activity

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-21T18:00:00Z - Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Aardvark Therapeutics (AARD).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

AARD_OUT_3 [2025-04-28 13:21:01 -0400] 974 Bytes | 298 tokens | Cum: 1272 tkns (15.90% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-25T06:50:14Z - Aardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% - What's Next?...
A2 - 2025-04-16T09:21:11Z - Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Aard...
A3 - 2025-04-09T17:06:21Z - 12 Health Care Stocks Moving In Wednesday's Intraday Session - Aardvark Therapeutics (NASDAQ:AARD), ...
A4 - 2025-04-03T16:00:29Z - Aardvark Therapeutics (NASDAQ:AARD) Earns "Outperform" Rating from Royal Bank of Canada...
A5 - 2025-04-02T15:39:15Z - Aardvark Therapeutics' (AARD) "Overweight" Rating Reiterated at Cantor Fitzgerald...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

AARD_OUT_5 [2025-04-28 13:21:02 -0400] 1181 Bytes | 341 tokens | Cum: 1615 tkns (20.19% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Aardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% - What's Next?**Date: 2025-04-25Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/aardvark-therapeutics-nasdaqaard-trading-up-76-whats-next-2025-04-23/Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) rose 7.6% on Tuesday . The stock traded as high as $7.88 and last traded at $7.66. Approximately 82,143 shares were traded during trading, a decline of 40% from the average daily volume of 135,957 shares. The stock had previously closed at $7.12.

Several equities research analysts have recently commented on the stock. Bank of America upped their price target on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Cantor Fitzgerald reiterated an "overweight" rating and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_7 [2025-04-28 13:21:03 -0400] 1181 Bytes | 308 tokens | Cum: 1925 tkns (24.06% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): issued a $50.00 price target on shares of Aardvark Therapeutics in a research report on Tuesday, April 1st. Royal Bank of Canada reissued an "outperform" rating and set a $21.00 price objective on shares of Aardvark Therapeutics in a research report on Tuesday, April 1st. Finally, Morgan Stanley assumed coverage on Aardvark Therapeutics in a report on Monday, March 10th. They issued an "overweight" rating and a $29.00 target price on the stock.

View Our Latest Analysis on Aardvark Therapeutics

The business's 50-day moving average price is $9.95.

In other Aardvark Therapeutics news, CFO Nelson Sun purchased 10,000 shares of the company's stock in a transaction dated Friday, February 14th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $160,000.00. Following the completion of the purchase, the chief financial officer now owns 99,484 shares

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_9 [2025-04-28 13:21:04 -0400] 1181 Bytes | 298 tokens | Cum: 2225 tkns (27.81% of 8k)
==========================================================================

Showing A1 (chunk 3 of 5): of the company's stock, valued at approximately $1,591,744. The trade was a 11.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Tien-Li Lee bought 16,542 shares of the company's stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the transaction, the chief executive officer now owns 1,496,175 shares in the company, valued at $23,938,800. The trade was a 1.12 % increase in their position. The disclosure for this purchase can be found here.

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered i

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_11 [2025-04-28 13:21:04 -0400] 1181 Bytes | 258 tokens | Cum: 2485 tkns (31.06% of 8k)
==========================================================================

Showing A1 (chunk 4 of 5): n San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Aardvark Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.

While Aardvark Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are be

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_13 [2025-04-28 13:21:05 -0400] 293 Bytes | 87 tokens | Cum: 2574 tkns (32.17% of 8k)
==========================================================================

Showing A1 (chunk 5 of 5): tter buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_15 [2025-04-28 13:21:06 -0400] 1070 Bytes | 257 tokens | Cum: 2833 tkns (35.41% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K It em 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the CONS financial statements and related notes ...

S2 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond.

On March 31, 2025, Aardvark Therapeutics, Inc. issued a press release reporting its financial results for the year ended December 31, 2024 and providing a business update. The full text of the press release is furnished a...

S3 - 2025-03-31 10-K It em 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the CONS financial statements and related notes ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AARD_OUT_17 [2025-04-28 13:21:07 -0400] 1181 Bytes | 244 tokens | Cum: 3079 tkns (38.49% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
It em 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Annual Report. This discussion and other parts of this Annual Report contain forward-looking statements that involve risk, assumptions and uncertainties, such as statements of our plans, objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors, including those set forth under Part I, Item 1A, Risk Factors, of this Annual Report and elsewhere in this Annual Report. You should carefully read Part I, Item 1A,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_19 [2025-04-28 13:21:07 -0400] 1181 Bytes | 246 tokens | Cum: 3327 tkns (41.59% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): Risk Factors, of this Annual Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled Special Note Regarding Forward-Looking Statements.

Overview

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients. We have focused our efforts on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Our initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_21 [2025-04-28 13:21:08 -0400] 1181 Bytes | 292 tokens | Cum: 3621 tkns (45.26% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): s. Our research has shown that activating these receptors can induce secretion of endogenous signaling molecules, including cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1). Our wholly-owned lead product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which we have initiated a Phase 3 clinical trial for hyperphagia associated with PWS. We also intend to evaluate ARD-101 in a Phase 2 clinical trial for hyperphagia associated with HO. In our completed Phase 2 clinical trial in subjects with hyperphagia associated with PWS, ARD-101 was shown to be well-tolerated and demonstrated clinical activity through a reduction in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score. We have aligned with the FDA on a protocol for a potentially pivotal Phase 3 clinical trial, which we initiated in December 2024, and we

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_23 [2025-04-28 13:21:09 -0400] 1181 Bytes | 255 tokens | Cum: 3878 tkns (48.48% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): anticipate topline data will be available in early 2026. In furtherance of preparing for this potentially pivotal Phase 3 clinical trial, we have expanded our clinical management and regulatory capabilities, including hiring clinical, regulatory and quality personnel, and we expect to continue to need to expand our clinical management and regulatory capabilities and to rely on third parties to conduct our pivotal clinical trials.

Below is a summary of our portfolio of novel and proprietary small molecule programs that we believe can induce satiety in patients with hunger-associated indications.

Our Hunger Associated TAS2R Pipeline (1)(2)

Beyond our lead product candidate, ARD-101, and our ARD-201 program, we are also developing other programs for the potential treatment of indications with high unmet need, including other indications mediated by TAS2R signaling.

Since we commenc

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_25 [2025-04-28 13:21:10 -0400] 1181 Bytes | 261 tokens | Cum: 4141 tkns (51.76% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): ed operations in 2017, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, discovering ARD-101, establishing and maintaining our intellectual property portfolio, conducting research, preclinical studies, and clinical trials, manufacturing of ARD-101 and related raw materials, and providing general and administrative support for these operations.

We have incurred significant net losses and negative cash flows from operations since our inception and, as of December 31, 2024, we had an accumulated deficit of $58.3 million. Our net losses for the years ended December 31, 2024 and 2023 were $20.6 million and $7.2 million, respectively. We expect our expenses and operating losses will increase substantially for the foreseeable future as we:

continue our development of, seek regulatory approval for, and potentially

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_27 [2025-04-28 13:21:10 -0400] 790 Bytes | 170 tokens | Cum: 4313 tkns (53.91% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): commercialize ARD-101 and our other product candidates;

seek to discover and develop additional product candidates;

conduct our ongoing and planned clinical trials and preclinical studies;

continue our research and development activities;

utilize third parties to manufacture ARD-101 and our other product candidates and related raw materials;

hire additional personnel;

maintain, expand and protect our intellectual property;

implement operational, financial and management informat...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

AARD_OUT_29 [2025-04-28 13:21:17 -0400] 6061 Bytes | 1539 tokens | Cum: 5854 tkns (73.17% of 8k)
==========================================================================

This is our set of metrics for Aardvark Therapeutics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 10,472 | Perf Month: 4.61% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 163.13K | Perf Quarter: - | Short Float: 2.25% | ROE: - |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.11 | Index: - | Short Ratio: 1.71 | ROI: - |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 54.90 | Market Cap: 201.99M | Short Interest: 0.28M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 1.16 | Shs Outstand: 21.70M | Beta: - | EPS Surprise: 39.02% |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: 17.79% | Shs Float: 12.39M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -6.07% | Inst Own: 10.05% | Sales past 5Y: 0.00% | Earnings: Mar 31 AMC |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -6.88% | Insider Own: 42.89% | Employees: 22 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: 30.76% | Insider Trans: 18.67% | Debt/Eq: - | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading by Aardvark Therapeutics officers or majority shareholders (if available).

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Cormorant Asset Management, LP (Unknown Title) on 2025-02-14
- Common Stock: 800189 shares at $N/A (I)
- Common Stock: 187500 shares at $16 (I)
- Series C Convertible Preferred Stock: 6780810 shares at $N/A (I)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Sun Nelson (Chief Financial Officer) on 2025-02-14
- Common Stock: 7001 shares at $N/A (D)
- Common Stock: 10000 shares at $16 (D)
- Series C Convertible Preferred Stock: 59332 shares at $0 (D)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Lee Tien-Li (Chief Executive Officer) on 2025-02-14
- Common Stock: 41303 shares at $N/A (D)
- Common Stock: 16542 shares at $16 (D)
- Series A Convertible Preferred Stock: 350002 shares at $0 (D)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Vickers Venture Fund VI Pte Ltd (Unknown Title) on 2025-02-14
- Common Stock: 1637411 shares at $N/A (I)
- Common Stock: 413491 shares at $N/A (I)
- Series A Convertible Preferred Stock: 13875429 shares at $0 (I)
- Series B Convertible Preferred Stock: 3503919 shares at $0 (I)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 9.235
Average Volume: 118629.3
30-Day High: 9.35
30-Day Low: 7
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Aardvark Therapeutics (AARD).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Aardvark Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because AARD is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for AARD.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, AARD could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect AARD to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Aardvark Therapeutics.

11) ETHICAL_RATING[]
Rate Aardvark Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Aardvark Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

AARD_IN_31 [2025-04-28 13:21:17 -0400] 126 Bytes | 29 tokens | Cum: 6115 tkns (76.44% of 8k)
==========================================================================

====================================
[2025-04-28 13:21:17] # Analysis Completed
Elapsed Time: 17.88 seconds